https://m2.mtmt.hu/ hun 2026-09-22 22:44 JournalArticle 35430277 VALIDATED true Megosztott utolsó szerzőség 0 false 2026-09-22T08:06:21.534+0000 2025-04-25T07:26:26.434+0000 2024-10-02T06:44:23.633+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 2026-04-15T14:23:06.986+0000 2025-04-25T07:26:26.619+0000 true 10099440 Csernyik Rita /api/admin/10099440 Admin Csernyik Rita (MTMT központi admin) true Admin 10099440 /api/admin/10099440 Csernyik Rita (MTMT központi admin) Csernyik Rita true true 2025-04-25T06:19:56.289+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Bojtor, Bence true true /api/journal/10003252 REVIEWED INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 true false 10003252 false 10003252 true 1661-6596 1422-0067 Journal FOREIGN 25 19 10488 10488 17 2024 Medication-related osteonecrosis of the jaw (MRONJ) is a rare side effect of antiresorptive drugs that significantly hinders the quality of life of affected patients. The disease develops in the presence of a combination of factors. Important pathogenetic factors include inflammation, inhibition of bone remodeling, or genetic predisposition. Since the first description of this rare side effect in 2003, a growing body of data has suggested a possible role for genetic factors in the disease. Several genes have been suggested to play an important role in the pathogenesis of MRONJ such as SIRT1, VEGFA, and CYP2C8. With the development of molecular biology, newer methods such as miRNA and gene expression studies have been introduced in MRONJ, in addition to methods that can examine the base sequence of the DNA. Describing the complex genetic background of MRONJ can help further understand its pathophysiology as well as identify new therapeutic targets to better manage this adverse drug reaction. Funding 2044910 /api/funding/2044910 (2020- 4.1.1.-TKP2020-MOLORKIV) false true Funding 2044911 /api/funding/2044911 (SE-ELKH ENDOMOLPAT) false true true true 2024 true true true false true false GOLD 2026-09-22 true https://doi.org/10.3390/ijms251910488 9 0 9 8 1 8 8 6 6 6 6 5 5 8 1 0 9 8 9 8 0 5 5 Folyóiratcikk Journal Article 24 9 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 2 2 2 2 2026 0 7 6 7 6 D1 false false false false 2024-10-01T06:44:29.718+0000 Arc- Állcsont- Szájsebészeti és Fogászati Klinika (SE / FOK); Belgyógyászati és Onkológiai Klinika (SE / AOK / K); HUN-REN-SE Endokrin Molekuláris Patológiai Kuta... (SE / AOK / K / BOK) 7 16 3 7 0 true 10099440 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 120730154 /api/authorship/120730154 Bojtor, Bence [Bojtor, Bence (Endokrinológia), szerző] Belgyógyászati és Onkológiai Klinika (SE / AOK / K) 1 0.143 true false false Author 10094857 /api/author/10094857 Bojtor Bence (Endokrinológia) Bojtor Bence true true Bojtor Bence true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 120730155 /api/authorship/120730155 Balla, Bernadett [Balla, Bernadett (oszteoporozis), szerző] HUN-REN-SE Endokrin Molekuláris Patológiai Kuta... (SE / AOK / K / BOK) 2 0.143 false false false Author 10024611 /api/author/10024611 Balla Bernadett (oszteoporozis) Balla Bernadett true 10024611 true Balla Bernadett true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 120730156 /api/authorship/120730156 Vaszilko, Mihaly [Vaszilkó, Mihály Tamás (Arc-Állcsont és S...), szerző] Arc- Állcsont- Szájsebészeti és Fogászati Klinika (SE / FOK) 3 0.143 false false false Author 10045854 /api/author/10045854 Vaszilkó Mihály Tamás (Arc-Állcsont és Szájsebészet) Vaszilkó Mihály Tamás true 10045854 true Vaszilko Mihaly true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 120730157 /api/authorship/120730157 Szentpeteri, Szofia [Szentpéteri, Szófia Katalin (arc-, állcsont-, ...), szerző] Arc- Állcsont- Szájsebészeti és Fogászati Klinika (SE / FOK) 4 0.143 false false false Author 10067866 /api/author/10067866 Szentpéteri Szófia Katalin (arc-, állcsont-, szájsebészet, egészség-gazdaságtan, logisztika) Szentpéteri Szófia Katalin true true Szentpeteri Szofia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 120730158 /api/authorship/120730158 Putz, Zsuzsanna [Putz, Zsuzsanna (Belgyógyászat, di...), szerző] Belgyógyászati és Onkológiai Klinika (SE / AOK / K); HUN-REN-SE Endokrin Molekuláris Patológiai Kuta... (SE / AOK / K / BOK) 5 0.143 false false false Author 10013989 /api/author/10013989 Putz Zsuzsanna (Belgyógyászat, diabetológia, klinikofarmakológia) Putz Zsuzsanna true 10013989 true Putz Zsuzsanna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 120730159 /api/authorship/120730159 Kosa, Janos P.** [Kósa, János (molekuláris biológia), szerző] Belgyógyászati és Onkológiai Klinika (SE / AOK / K); HUN-REN-SE Endokrin Molekuláris Patológiai Kuta... (SE / AOK / K / BOK) 6 0.143 false true false Author 10024099 /api/author/10024099 Kósa János (molekuláris biológia) Kósa János true 10024099 true Kosa Janos P. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 120730160 /api/authorship/120730160 Lakatos, Peter ✉ [Lakatos, Péter (Osteológia, endok...), szerző] Belgyógyászati és Onkológiai Klinika (SE / AOK / K); HUN-REN-SE Endokrin Molekuláris Patológiai Kuta... (SE / AOK / K / BOK) 7 0.143 false true true Author 10012016 /api/author/10012016 Lakatos Péter (Osteológia, endokrinológia, molekuláris biológia) Lakatos Péter true 10012016 true Lakatos Peter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 27571589 /api/publicationidentifier/27571589 DOI: 10.3390/ijms251910488 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3390/ijms251910488 https://doi.org/10.3390/ijms251910488 false true PublicationIdentifier 27671659 /api/publicationidentifier/27671659 WoS: 001332401600001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001332401600001 https://www.webofscience.com/wos/woscc/full-record/001332401600001 true true PublicationIdentifier 27678268 /api/publicationidentifier/27678268 Scopus: 85206341318 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85206341318 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85206341318 true true PublicationIdentifier 27661657 /api/publicationidentifier/27661657 PubMed: 39408816 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39408816 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39408816&dopt=Abstract true true Classification 12215 /api/classification/12215 Klinikai orvostan true true SjrRating 11489344 /api/sjrrating/11489344 sjr:D1 (2024) Scopus - Organic Chemistry INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 18 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1605 /api/classificationexternal/1605 Scopus - Organic Chemistry true 1605 true D1 DIRECT true true Reference 58385713 /api/reference/58385713 1. Ruggiero 2022: American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update., J. Oral Maxillofac. Surg., 80, p. 920, DOI: 10.1016/j.joms.2022.02.008 1 10.1016/j.joms.2022.02.008 false true Reference 58385714 /api/reference/58385714 2. Russell 2008: Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy., Osteoporos. Int., 19, p. 733, DOI: 10.1007/s00198-007-0540-8 2 10.1007/s00198-007-0540-8 false true Reference 58385715 /api/reference/58385715 3. Hanley 2012: Denosumab: Mechanism of action and clinical outcomes., Int. J. Clin. Pract., 66, p. 1139, DOI: 10.1111/ijcp.12022 3 10.1111/ijcp.12022 false true Reference 58385716 /api/reference/58385716 4. Cadieux 2022: Experience with denosumab (XGEVA(R)) for prevention of skeletal-related events in the 10 years after approval., J. Bone Oncol., 33, p. 100416, DOI: 10.1016/j.jbo.2022.100416 4 10.1016/j.jbo.2022.100416 false true Reference 58385717 /api/reference/58385717 5. Ross 2003: Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer., BMJ, 327, p. 469, DOI: 10.1136/bmj.327.7413.469 5 10.1136/bmj.327.7413.469 false true Reference 58385718 /api/reference/58385718 6. Marx 2003: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic., J. Oral Maxillofac. Surg., 61, p. 1115, DOI: 10.1016/S0278-2391(03)00720-1 6 10.1016/S0278-2391(03)00720-1 false true Reference 58385719 /api/reference/58385719 7. Ruggiero 2014: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update., J. Oral Maxillofac. Surg., 72, p. 1938, DOI: 10.1016/j.joms.2014.04.031 7 10.1016/j.joms.2014.04.031 false true Reference 58385720 /api/reference/58385720 8. De Cicco, D., Boschetti, C.E., Santagata, M., Colella, G., Stagliano, S., Gaggl, A., Bottini, G.B., Vitagliano, R., and D’Amato, S. (2023). Medication-Related Osteonecrosis of the Jaws: A Comparison of SICMF-SIPMO and AAOMS Guidelines. Diagnostics, 13., DOI: 10.3390/diagnostics13132137 8 10.3390/diagnostics13132137 false true Reference 58385721 /api/reference/58385721 9. Bedogni 2024: Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)., Oral Dis., 30, p. 3679, DOI: 10.1111/odi.14887 9 10.1111/odi.14887 false true Reference 58385722 /api/reference/58385722 10. Bensi 2021: Quality of life in patients affected by medication-related osteonecrosis of the jaws: A systematic review., Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 132, p. 182, DOI: 10.1016/j.oooo.2021.03.006 10 10.1016/j.oooo.2021.03.006 false true Reference 58385723 /api/reference/58385723 11. Miksad 2011: Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw., Oncologist, 16, p. 121, DOI: 10.1634/theoncologist.2010-0183 11 10.1634/theoncologist.2010-0183 false true Reference 58385724 /api/reference/58385724 12. Munakata 2024: Factors affecting the quality of life of patients with medication-related osteonecrosis of the jaw during treatment: A quality-of-life survey and causal analysis., J. Cranio-Maxillofac. Surg., 52, p. 715, DOI: 10.1016/j.jcms.2024.03.021 12 10.1016/j.jcms.2024.03.021 false true Reference 58385725 /api/reference/58385725 13. Kalita 2023: Osteonecrosis of the Jaws: An Update and Review of Literature., J. Oral Maxillofac. Surg., 22, p. 344, DOI: 10.1007/s12663-023-01876-w 13 10.1007/s12663-023-01876-w false true Reference 58385726 /api/reference/58385726 14. Guo 2020: Pharmacogenetics of medication-related osteonecrosis of the jaw: A systematic review and meta-analysis., Int. J. Oral Maxillofac. Surg., 49, p. 298, DOI: 10.1016/j.ijom.2019.07.016 14 10.1016/j.ijom.2019.07.016 false true Reference 58385727 /api/reference/58385727 15. Musolino 2018: Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw., Ann. Hematol., 97, p. 1259, DOI: 10.1007/s00277-018-3296-7 15 10.1007/s00277-018-3296-7 false true Reference 58385728 /api/reference/58385728 16. Yang 2018: Circulating microRNA Panel as a Novel Biomarker to Diagnose Bisphosphonate-Related Osteonecrosis of the Jaw., Int. J. Med. Sci., 15, p. 1694, DOI: 10.7150/ijms.27593 16 10.7150/ijms.27593 false true Reference 58385729 /api/reference/58385729 17. Lian 2012: MicroRNA control of bone formation and homeostasis., Nat. Rev. Endocrinol., 8, p. 212, DOI: 10.1038/nrendo.2011.234 17 10.1038/nrendo.2011.234 false true Reference 58385730 /api/reference/58385730 18. Thiel 2020: Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw., Pathol. Res. Pract., 216, p. 153245, DOI: 10.1016/j.prp.2020.153245 18 10.1016/j.prp.2020.153245 false true Reference 58385731 /api/reference/58385731 19. He 2021: Immune-related expression profiles of bisphosphonates-related osteonecrosis of the jaw in multiple myeloma., Pharmazie, 76, p. 159 19 false true Reference 58385732 /api/reference/58385732 20. Aibar-Almazan, A., Voltes-Martinez, A., Castellote-Caballero, Y., Afanador-Restrepo, D.F., Carcelen-Fraile, M.D.C., and Lopez-Ruiz, E. (2022). Current Status of the Diagnosis and Management of Osteoporosis. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms23169465 20 10.3390/ijms23169465 false true Reference 58385733 /api/reference/58385733 21. Lyu 2019: Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials., J. Clin. Endocrinol. Metab., 104, p. 1753, DOI: 10.1210/jc.2018-02236 21 10.1210/jc.2018-02236 false true Reference 58385734 /api/reference/58385734 22. Kravets 2018: Paget’s Disease of Bone: Diagnosis and Treatment., Am. J. Med., 131, p. 1298, DOI: 10.1016/j.amjmed.2018.04.028 22 10.1016/j.amjmed.2018.04.028 false true Reference 58385735 /api/reference/58385735 23. Marom 2020: Osteogenesis imperfecta: An update on clinical features and therapies., Eur. J. Endocrinol., 183, p. R95, DOI: 10.1530/EJE-20-0299 23 10.1530/EJE-20-0299 false true Reference 58385736 /api/reference/58385736 24. Riddle 2013: Fibrous dysplasia., Arch. Pathol. Lab. Med., 137, p. 134, DOI: 10.5858/arpa.2012.0013-RS 24 10.5858/arpa.2012.0013-RS false true Reference 58385737 /api/reference/58385737 25. Soundia 2016: Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease., Bone, 90, p. 133, DOI: 10.1016/j.bone.2016.06.011 25 10.1016/j.bone.2016.06.011 false true Reference 58385738 /api/reference/58385738 26. Kuroshima 2014: Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing., Osteoporos. Int., 25, p. 1141, DOI: 10.1007/s00198-013-2570-8 26 10.1007/s00198-013-2570-8 false true Reference 58385739 /api/reference/58385739 27. Wein 2018: Regulation of Bone Remodeling by Parathyroid Hormone., Cold Spring Harb Perspect. Med., 8, p. a031237, DOI: 10.1101/cshperspect.a031237 27 10.1101/cshperspect.a031237 false true Reference 58385740 /api/reference/58385740 28. Anitua 2016: PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells., Clin. Oral Investig., 20, p. 513, DOI: 10.1007/s00784-015-1528-y 28 10.1007/s00784-015-1528-y false true Reference 58385741 /api/reference/58385741 29. Ohlrich 2016: The bisphosphonate zoledronic acid regulates key angiogenesis-related genes in primary human gingival fibroblasts., Arch. Oral Biol., 63, p. 7, DOI: 10.1016/j.archoralbio.2015.11.013 29 10.1016/j.archoralbio.2015.11.013 false true Reference 58385742 /api/reference/58385742 30. Chang 2018: Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw., Curr. Osteoporos. Rep., 16, p. 584, DOI: 10.1007/s11914-018-0474-4 30 10.1007/s11914-018-0474-4 false true Reference 58385743 /api/reference/58385743 31. Zhang, W., Gao, L., Ren, W., Li, S., Zheng, J., Li, S., Jiang, C., Yang, S., and Zhi, K. (2021). The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw. Front. Immunol., 12., DOI: 10.3389/fimmu.2021.606043 31 10.3389/fimmu.2021.606043 false true Reference 58385744 /api/reference/58385744 32. Maciel 2024: Etiopathogenesis of medication-related osteonecrosis of the jaws: A review., J. Mol. Med., 102, p. 353, DOI: 10.1007/s00109-024-02425-9 32 10.1007/s00109-024-02425-9 false true Reference 58385745 /api/reference/58385745 33. Hadaya 2019: Development of Medication-Related Osteonecrosis of the Jaw After Extraction of Teeth With Experimental Periapical Disease., J. Oral Maxillofac. Surg., 77, p. 71, DOI: 10.1016/j.joms.2018.08.010 33 10.1016/j.joms.2018.08.010 false true Reference 58385746 /api/reference/58385746 34. Nakamura 2024: Risk factors for the development of medication-related osteonecrosis of the jaw and effects of tooth extraction with local infection., J. Dent. Sci., 19, p. 1770, DOI: 10.1016/j.jds.2023.10.006 34 10.1016/j.jds.2023.10.006 false true Reference 58385747 /api/reference/58385747 35. Wood 2002: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid., J. Pharmacol. Exp. Ther., 302, p. 1055, DOI: 10.1124/jpet.102.035295 35 10.1124/jpet.102.035295 false true Reference 58385748 /api/reference/58385748 36. Libouban 2018: Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: An experimental study in the rat., Clin. Oral Investig., 22, p. 2997, DOI: 10.1007/s00784-018-2385-2 36 10.1007/s00784-018-2385-2 false true Reference 58385749 /api/reference/58385749 37. Sharma, D., Hamlet, S., Vaquette, C., Petcu, E.B., Ramamurthy, P., and Ivanovski, S. (2021). Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw. Sci. Rep., 11., DOI: 10.1038/s41598-021-02637-w 37 10.1038/s41598-021-02637-w false true Reference 58385750 /api/reference/58385750 38. Bastos 2017: In-vivo imaging of the microvasculature of the soft tissue margins of osteonecrotic jaw lesions., Br. Dent. J., 223, p. 699, DOI: 10.1038/sj.bdj.2017.888 38 10.1038/sj.bdj.2017.888 false true Reference 58385751 /api/reference/58385751 39. Lai 2009: Human CYP2C8: Structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms., Curr. Drug Metab., 10, p. 1009, DOI: 10.2174/138920009790711832 39 10.2174/138920009790711832 false true Reference 58385752 /api/reference/58385752 40. Yamoune 2022: Role of cytochrome P450 2C8 genetic polymorphism and epoxygenase uncoupling in periodontal remodelling affecting orthodontic treatment., Basic Clin. Pharmacol. Toxicol., 130, p. 132, DOI: 10.1111/bcpt.13681 40 10.1111/bcpt.13681 false true Reference 58385753 /api/reference/58385753 41. Tamaoka 2019: Osteonecrosis of the jaws caused by bisphosphonate treatment and oxidative stress in mice., Exp. Ther. Med., 17, p. 1440 41 false true Reference 58385754 /api/reference/58385754 42. Capdevila 2000: Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase., J. Lipid Res., 41, p. 163, DOI: 10.1016/S0022-2275(20)32049-6 42 10.1016/S0022-2275(20)32049-6 false true Reference 58385755 /api/reference/58385755 43. Viccica 2007: Role of the cholesterol biosynthetic pathway in osteoblastic differentiation., J. Endocrinol. Investig., 30, p. 8 43 false true Reference 58385756 /api/reference/58385756 44. Sarasquete 2008: Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis., Blood, 112, p. 2709, DOI: 10.1182/blood-2008-04-147884 44 10.1182/blood-2008-04-147884 false true Reference 58385757 /api/reference/58385757 45. English 2010: A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer., Ther. Clin. Risk Manag., 6, p. 579 45 false true Reference 58385758 /api/reference/58385758 46. Katz 2011: Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw., Int. J. Oral Maxillofac. Surg., 40, p. 605, DOI: 10.1016/j.ijom.2011.02.002 46 10.1016/j.ijom.2011.02.002 false true Reference 58385759 /api/reference/58385759 47. Such 2011: CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma., Haematologica, 96, p. 1557, DOI: 10.3324/haematol.2011.042572 47 10.3324/haematol.2011.042572 false true Reference 58385760 /api/reference/58385760 48. Balla 2012: New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw., Oral Dis., 18, p. 580, DOI: 10.1111/j.1601-0825.2012.01912.x 48 10.1111/j.1601-0825.2012.01912.x false true Reference 58385761 /api/reference/58385761 49. Kastritis 2017: Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy., Leuk. Lymphoma, 58, p. 2304, DOI: 10.1080/10428194.2017.1300889 49 10.1080/10428194.2017.1300889 false true Reference 58385762 /api/reference/58385762 50. Zhong 2013: Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: A meta-analysis., Acta Haematol., 129, p. 90, DOI: 10.1159/000342120 50 10.1159/000342120 false true Reference 58385763 /api/reference/58385763 51. Wu 2022: The sirtuin family in health and disease., Signal Transduct. Target. Ther., 7, p. 402, DOI: 10.1038/s41392-022-01257-8 51 10.1038/s41392-022-01257-8 false true Reference 58385764 /api/reference/58385764 52. Chen 2021: SIRT1, a promising regulator of bone homeostasis., Life Sci., 269, p. 119041, DOI: 10.1016/j.lfs.2021.119041 52 10.1016/j.lfs.2021.119041 false true Reference 58385765 /api/reference/58385765 53. Zainabadi, K., Liu, C.J., Caldwell, A.L.M., and Guarente, L. (2017). SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. PLoS ONE, 12., DOI: 10.1371/journal.pone.0185236 53 10.1371/journal.pone.0185236 false true Reference 58385766 /api/reference/58385766 54. Ornstrup 2014: Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: A randomized placebo-controlled trial., J. Clin. Endocrinol. Metab., 99, p. 4720, DOI: 10.1210/jc.2014-2799 54 10.1210/jc.2014-2799 false true Reference 58385767 /api/reference/58385767 55. Zhu 2024: Inflammation Can Be a High-Risk Factor for Mucosal Nonunion of MRONJ by Regulating SIRT1 Signaling When Treated with an Oncologic Dose of Zoledronate., Drug Des. Dev. Ther., 18, p. 2793, DOI: 10.2147/DDDT.S456811 55 10.2147/DDDT.S456811 false true Reference 58385768 /api/reference/58385768 56. Cui 2023: Menaquinone-4 prevents medication-related osteonecrosis of the jaw through the SIRT1 signaling-mediated inhibition of cellular metabolic stresses-induced osteoblast apoptosis., Free Radic. Biol. Med., 206, p. 33, DOI: 10.1016/j.freeradbiomed.2023.06.022 56 10.1016/j.freeradbiomed.2023.06.022 false true Reference 58385769 /api/reference/58385769 57. Yang 2018: SIRT1/HERC4 Locus Associated With Bisphosphonate-Induced Osteonecrosis of the Jaw: An Exome-Wide Association Analysis., J. Bone Miner. Res., 33, p. 91, DOI: 10.1002/jbmr.3285 57 10.1002/jbmr.3285 false true Reference 58385770 /api/reference/58385770 58. Yang 2021: SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw., J. Bone Miner. Res., 36, p. 347, DOI: 10.1002/jbmr.4185 58 10.1002/jbmr.4185 false true Reference 58385771 /api/reference/58385771 59. Bojtor, B., Vaszilko, M., Armos, R., Tobias, B., Podani, J., Szentpeteri, S., Balla, B., Lengyel, B., Piko, H., and Illes, A. (2024). Analysis of SIRT1 Gene SNPs and Clinical Characteristics in Medication-Related Osteonecrosis of the Jaw. Int. J. Mol. Sci., 25., DOI: 10.3390/ijms25073646 59 10.3390/ijms25073646 false true Reference 58385772 /api/reference/58385772 60. Emmanuelle, N.E., Marie-Cecile, V., Florence, T., Jean-Francois, A., Francoise, L., Coralie, F., and Alexia, V. (2021). Critical Role of Estrogens on Bone Homeostasis in Both Male and Female: From Physiology to Medical Implications. Int. J. Mol. Sci., 22., DOI: 10.3390/ijms22041568 60 10.3390/ijms22041568 false true Reference 58385773 /api/reference/58385773 61. Pacifici 1989: Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release., Proc. Natl. Acad. Sci. USA, 86, p. 2398, DOI: 10.1073/pnas.86.7.2398 61 10.1073/pnas.86.7.2398 false true Reference 58385774 /api/reference/58385774 62. Jilka 1992: Increased osteoclast development after estrogen loss: Mediation by interleukin-6., Science, 257, p. 88, DOI: 10.1126/science.1621100 62 10.1126/science.1621100 false true Reference 58385775 /api/reference/58385775 63. Kousteni 2001: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity., Cell, 104, p. 719 63 false true Reference 58385776 /api/reference/58385776 64. Bord 2003: The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts., Bone, 32, p. 136, DOI: 10.1016/S8756-3282(02)00953-5 64 10.1016/S8756-3282(02)00953-5 false true Reference 58385777 /api/reference/58385777 65. Kahlert 2000: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway., J. Biol. Chem., 275, p. 18447, DOI: 10.1074/jbc.M910345199 65 10.1074/jbc.M910345199 false true Reference 58385778 /api/reference/58385778 66. Emmerson 2012: Insulin-like growth factor-1 promotes wound healing in estrogen-deprived mice: New insights into cutaneous IGF-1R/ERalpha cross talk., J. Investig. Dermatol., 132, p. 2838, DOI: 10.1038/jid.2012.228 66 10.1038/jid.2012.228 false true Reference 58385779 /api/reference/58385779 67. Choi, S.Y., Kim, J.W., Oh, S.H., Cheon, S., Yee, J., Kim, S.J., Gwak, H.S., and Chung, J.E. (2023). Prediction of medication-related osteonecrosis of the jaws using machine learning methods from estrogen receptor 1 polymorphisms and clinical information. Front. Med., 10., DOI: 10.3389/fmed.2023.1140620 67 10.3389/fmed.2023.1140620 false true Reference 58385780 /api/reference/58385780 68. Liu 2018: ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies., J. Cancer, 9, p. 2963, DOI: 10.7150/jca.25638 68 10.7150/jca.25638 false true Reference 58385781 /api/reference/58385781 69. Casazza 2010: The association between the rs2234693 and rs9340799 estrogen receptor alpha gene polymorphisms and risk factors for cardiovascular disease: A review., Biol. Res. Nurs., 12, p. 84, DOI: 10.1177/1099800410371118 69 10.1177/1099800410371118 false true Reference 58385782 /api/reference/58385782 70. Boot 2004: Estrogen receptor alpha gene polymorphisms and bone mineral density in healthy children and young adults., Calcif. Tissue Int., 74, p. 495, DOI: 10.1007/s00223-003-0168-4 70 10.1007/s00223-003-0168-4 false true Reference 58385783 /api/reference/58385783 71. Gennari 2011: Aromatase activity and bone loss., Adv. Clin. Chem., 54, p. 129, DOI: 10.1016/B978-0-12-387025-4.00006-6 71 10.1016/B978-0-12-387025-4.00006-6 false true Reference 58385784 /api/reference/58385784 72. Hernandez 2008: Aromatase expression in osteoarthritic and osteoporotic bone., Arthritis Rheumatol., 58, p. 1696, DOI: 10.1002/art.23500 72 10.1002/art.23500 false true Reference 58385785 /api/reference/58385785 73. Paolicchi 2012: An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw., Biomark. Med., 6, p. 201, DOI: 10.2217/bmm.12.14 73 10.2217/bmm.12.14 false true Reference 58385786 /api/reference/58385786 74. Dunning 2004: Polymorphisms associated with circulating sex hormone levels in postmenopausal women., J. Natl. Cancer Inst., 96, p. 936, DOI: 10.1093/jnci/djh167 74 10.1093/jnci/djh167 false true Reference 58385787 /api/reference/58385787 75. Adam, M.P. (1993). COL1A1/2 Osteogenesis Imperfecta. GeneReviews®, University of Washington. 75 false true Reference 58385788 /api/reference/58385788 76. Wang 2017: Association of polymorphisms rs1800012 in COL1A1 with sports-related tendon and ligament injuries: A meta-analysis., Oncotarget, 8, p. 27627, DOI: 10.18632/oncotarget.15271 76 10.18632/oncotarget.15271 false true Reference 58385789 /api/reference/58385789 77. Liu 2010: Structural and functional insights of RANKL-RANK interaction and signaling., J. Immunol., 184, p. 6910, DOI: 10.4049/jimmunol.0904033 77 10.4049/jimmunol.0904033 false true Reference 58385790 /api/reference/58385790 78. Boyce 2007: Biology of RANK, RANKL, and osteoprotegerin., Arthritis Res. Ther., 9, p. S1, DOI: 10.1186/ar2165 78 10.1186/ar2165 false true Reference 58385791 /api/reference/58385791 79. Tu 2015: Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women., Osteoporos. Int., 26, p. 179, DOI: 10.1007/s00198-014-2854-7 79 10.1007/s00198-014-2854-7 false true Reference 58385792 /api/reference/58385792 80. Koo 2012: Dimerization of matrix metalloproteinase-2 (MMP-2): Functional implication in MMP-2 activation., J. Biol. Chem., 287, p. 22643, DOI: 10.1074/jbc.M111.337949 80 10.1074/jbc.M111.337949 false true Reference 58385793 /api/reference/58385793 81. Lehrer 2009: Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene., J. Oral Maxillofac. Surg., 67, p. 159, DOI: 10.1016/j.joms.2008.09.015 81 10.1016/j.joms.2008.09.015 false true Reference 58385794 /api/reference/58385794 82. Ferrara 2003: The biology of VEGF and its receptors., Nat. Med., 9, p. 669, DOI: 10.1038/nm0603-669 82 10.1038/nm0603-669 false true Reference 58385795 /api/reference/58385795 83. Yao 2004: Increase of both angiogenesis and bone mass in response to exercise depends on VEGF., J. Bone Miner. Res., 19, p. 1471, DOI: 10.1359/JBMR.040517 83 10.1359/JBMR.040517 false true Reference 58385796 /api/reference/58385796 84. Yang 2020: Association of VEGF Gene Polymorphisms with Susceptibility to Diabetic Retinopathy: A Systematic Review and Meta-Analysis., Horm. Metab. Res., 52, p. 264, DOI: 10.1055/a-1143-6024 84 10.1055/a-1143-6024 false true Reference 58385797 /api/reference/58385797 85. Wu 2017: Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: A meta-analysis., Br. J. Ophthalmol., 101, p. 976, DOI: 10.1136/bjophthalmol-2016-309418 85 10.1136/bjophthalmol-2016-309418 false true Reference 58385798 /api/reference/58385798 86. Koutras 2015: Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer., Pharmacogenomics, 16, p. 79, DOI: 10.2217/pgs.14.148 86 10.2217/pgs.14.148 false true Reference 58385799 /api/reference/58385799 87. Tang 2017: Association between vascular endothelial growth factor gene polymorphisms and the risk and prognosis of renal cell carcinoma: A systematic review and meta-analysis., Oncotarget, 8, p. 50034, DOI: 10.18632/oncotarget.17293 87 10.18632/oncotarget.17293 false true Reference 58385800 /api/reference/58385800 88. Liu 2014: Distinct VEGF functions during bone development and homeostasis., Arch. Immunol. Ther. Exp., 62, p. 363, DOI: 10.1007/s00005-014-0285-y 88 10.1007/s00005-014-0285-y false true Reference 58385801 /api/reference/58385801 89. Arduino 2011: Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws., J. Oral Pathol. Med., 40, p. 510, DOI: 10.1111/j.1600-0714.2010.01004.x 89 10.1111/j.1600-0714.2010.01004.x false true Reference 58385802 /api/reference/58385802 90. Renner 2000: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels., J. Vasc. Res., 37, p. 443, DOI: 10.1159/000054076 90 10.1159/000054076 false true Reference 58385803 /api/reference/58385803 91. Awata 2002: A common polymorphism in the 5’-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes., Diabetes, 51, p. 1635, DOI: 10.2337/diabetes.51.5.1635 91 10.2337/diabetes.51.5.1635 false true Reference 58385804 /api/reference/58385804 92. Shahbazi 2002: Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection., J. Am. Soc. Nephrol., 13, p. 260, DOI: 10.1681/ASN.V131260 92 10.1681/ASN.V131260 false true Reference 58385805 /api/reference/58385805 93. Choi 2015: Genetic association between VEGF polymorphisms and BRONJ in the Korean population., Oral Dis., 21, p. 866, DOI: 10.1111/odi.12355 93 10.1111/odi.12355 false true Reference 58385806 /api/reference/58385806 94. Kim, J.W., Yee, J., Oh, S.H., Kim, S.H., Kim, S.J., Chung, J.E., and Gwak, H.S. (2021). Machine Learning Approaches for Predicting Bisphosphonate-Related Osteonecrosis in Women with Osteoporosis Using VEGFA Gene Polymorphisms. J. Pers. Med., 11., DOI: 10.3390/jpm11060541 94 10.3390/jpm11060541 false true Reference 58385807 /api/reference/58385807 95. Kim, S., Mun, S., Shin, W., Han, K., and Kim, M.Y. (2022). Identification of Potentially Pathogenic Variants Associated with Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ) Patients Using Whole-Exome Sequencing. J. Clin. Med., 11., DOI: 10.3390/jcm11082145 95 10.3390/jcm11082145 false true Reference 58385808 /api/reference/58385808 96. Kimura 2013: Mutation of keratin 4 gene causing white sponge nevus in a Japanese family., Int. J. Oral Maxillofac. Surg., 42, p. 615, DOI: 10.1016/j.ijom.2012.10.030 96 10.1016/j.ijom.2012.10.030 false true Reference 58385809 /api/reference/58385809 97. Nicoletti 2012: Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: The role of RBMS3., Oncologist, 17, p. 279, DOI: 10.1634/theoncologist.2011-0202 97 10.1634/theoncologist.2011-0202 false true Reference 58385810 /api/reference/58385810 98. Arbitrio 2011: A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: Analysis by DMET microarray profiling., Br. J. Haematol., 154, p. 529, DOI: 10.1111/j.1365-2141.2011.08622.x 98 10.1111/j.1365-2141.2011.08622.x false true Reference 58385811 /api/reference/58385811 99. Reynolds 2022: Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer., Oral Dis., 28, p. 193, DOI: 10.1111/odi.13746 99 10.1111/odi.13746 false true Reference 58385812 /api/reference/58385812 100. Marini 2011: Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw., Front. Biosci., 3, p. 364 100 false true Reference 58385813 /api/reference/58385813 101. Coxon 2006: Recent advances in understanding the mechanism of action of bisphosphonates., Curr. Opin. Pharmacol., 6, p. 307, DOI: 10.1016/j.coph.2006.03.005 101 10.1016/j.coph.2006.03.005 false true Reference 58385814 /api/reference/58385814 102. Marini 2008: Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis., Curr. Med. Res. Opin., 24, p. 2609, DOI: 10.1185/03007990802352894 102 10.1185/03007990802352894 false true Reference 58385815 /api/reference/58385815 103. Szentpeteri, S., Kosa, J., Juhasz, H.D., Deak, G., Nemeth, Z., Lakatos, P., and Vaszilko, M. (2024). Examination of certain single-nucleotide polymorphisms of interleukins 1A and 1B in medication-related osteonecrosis of the jaw—An ambirectional cohort study. J. Cranio-Maxillofac. Surg., DOI: 10.1016/j.jcms.2024.06.007 103 10.1016/j.jcms.2024.06.007 false true Reference 58385816 /api/reference/58385816 104. Stockmann 2013: Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw., J. Cranio-Maxillofac. Surg., 41, p. 71, DOI: 10.1016/j.jcms.2012.10.018 104 10.1016/j.jcms.2012.10.018 false true Reference 58385817 /api/reference/58385817 105. Lee 2019: Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: A case control study., J. Transl. Med., 17, p. 381, DOI: 10.1186/s12967-019-2129-3 105 10.1186/s12967-019-2129-3 false true Reference 58385818 /api/reference/58385818 106. Sacco, R., Olate, S., Calasans-Maia, M.D., Sacco, N., Acocella, A., De Almeida Barros Mourão, C.F., Moraschini, V., Akintola, O., Guerra, R.C., and Yates, J. (2022). A Comprehensive Quality Meta-Review of Genetic and Pharmacogenomic Aspects of Medication-Related Osteonecrosis of The Jaw (MRONJ). Appl. Sci., 12., DOI: 10.3390/app122312289 106 10.3390/app122312289 false true Reference 58385819 /api/reference/58385819 107. Li, J.W., Wang, J.Y., Yu, R.Q., Huo, L., and Zheng, L.W. (2022). Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid. BMC Res. Notes, 15., DOI: 10.1186/s13104-021-05900-5 107 10.1186/s13104-021-05900-5 false true Reference 58385820 /api/reference/58385820 108. Ruiz 2018: Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw., Int. J. Med. Sci., 15, p. 359, DOI: 10.7150/ijms.22627 108 10.7150/ijms.22627 false true Reference 58385821 /api/reference/58385821 109. Wehrhan 2010: Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features., J. Transl. Med., 8, p. 96, DOI: 10.1186/1479-5876-8-96 109 10.1186/1479-5876-8-96 false true Reference 58385822 /api/reference/58385822 110. Kalyan 2015: Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw., J. Transl. Med., 13, p. 212, DOI: 10.1186/s12967-015-0568-z 110 10.1186/s12967-015-0568-z false true Reference 58385823 /api/reference/58385823 111. Sun 2015: Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma., Onco Targets Ther., 8, p. 2681, DOI: 10.2147/OTT.S88463 111 10.2147/OTT.S88463 false true Reference 58385824 /api/reference/58385824 112. Raje 2008: Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw., Clin. Cancer Res., 14, p. 2387, DOI: 10.1158/1078-0432.CCR-07-1430 112 10.1158/1078-0432.CCR-07-1430 false true Reference 58385825 /api/reference/58385825 113. Kim 2018: Identifying a combined biomarker for bisphosphonate-related osteonecrosis of the jaw., Clin. Implant Dent. Relat. Res., 20, p. 191, DOI: 10.1111/cid.12569 113 10.1111/cid.12569 false true Reference 58385826 /api/reference/58385826 114. Shi 2020: Stress response in periodontal ligament stem cells may contribute to bisphosphonate-associated osteonecrosis of the jaw: A gene expression array analysis., Mol. Med. Rep., 22, p. 2043, DOI: 10.3892/mmr.2020.11276 114 10.3892/mmr.2020.11276 false true Reference 58385827 /api/reference/58385827 115. Kuroshima 2021: Gene expression analysis of fresh extraction wounds prior to onset of bisphosphonate-related osteonecrosis of the jaw-like lesions in mice: A preliminary animal study., J. Prosthodont. Res., 65, p. 546, DOI: 10.2186/jpr.JPR_D_20_00027 115 10.2186/jpr.JPR_D_20_00027 false true Reference 58385828 /api/reference/58385828 116. Saliminejad 2019: An overview of microRNAs: Biology, functions, therapeutics, and analysis methods., J. Cell. Physiol., 234, p. 5451, DOI: 10.1002/jcp.27486 116 10.1002/jcp.27486 false true Reference 58385829 /api/reference/58385829 117. O’Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9., DOI: 10.3389/fendo.2018.00402 117 10.3389/fendo.2018.00402 false true Reference 58385830 /api/reference/58385830 118. Allegra, A., Mania, M., D’Ascola, A., Oteri, G., Siniscalchi, E.N., Avenoso, A., Innao, V., Scuruchi, M., Allegra, A.G., and Musolino, C. (2020). Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw. BioMed Res. Int., 2020., DOI: 10.1155/2020/9879876 118 10.1155/2020/9879876 false true Reference 58385831 /api/reference/58385831 119. Dong 2017: MicroRNA-23a-3p inhibitor decreases osteonecrosis incidence in a rat model., Mol. Med. Rep., 16, p. 9331, DOI: 10.3892/mmr.2017.7808 119 10.3892/mmr.2017.7808 false true Reference 58385832 /api/reference/58385832 120. Shen 2022: Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ., JCI Insight, 7, p. e159865, DOI: 10.1172/jci.insight.159865 120 10.1172/jci.insight.159865 false true Reference 58385833 /api/reference/58385833 121. Sim 2020: Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial., J. Clin. Oncol., 38, p. 2971, DOI: 10.1200/JCO.19.02192 121 10.1200/JCO.19.02192 false true Reference 58385834 /api/reference/58385834 122. Park 2017: Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?., J. Oral Maxillofac. Surg., 75, p. 1176, DOI: 10.1016/j.joms.2016.12.005 122 10.1016/j.joms.2016.12.005 false true /api/publication/35430277 Bojtor Bence et al. Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives. (2024) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 25 19<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10094857"><a href="/gui2/?type=authors&mode=browse&sel=10094857" target="_blank">Bojtor Bence (<span class="authorship-author-name">Bojtor Bence</span> <span class="authorAux-mtmt"> Endokrinológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Belgyógyászati és Onkológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024611"><a href="/gui2/?type=authors&mode=browse&sel=10024611" target="_blank">Balla Bernadett (<span class="authorship-author-name">Balla Bernadett</span> <span class="authorAux-mtmt"> oszteoporozis</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Belgyógyászati és Onkológiai Klinika">BOK</span>/HUN-REN-SE Endokrin Molekuláris Patológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10045854"><a href="/gui2/?type=authors&mode=browse&sel=10045854" target="_blank">Vaszilko Mihaly (<span class="authorship-author-name">Vaszilkó Mihály Tamás</span> <span class="authorAux-mtmt"> Arc-Állcsont és Szájsebészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Arc- Állcsont- Szájsebészeti és Fogászati Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10067866"><a href="/gui2/?type=authors&mode=browse&sel=10067866" target="_blank">Szentpeteri Szofia (<span class="authorship-author-name">Szentpéteri Szófia Katalin</span> <span class="authorAux-mtmt"> arc-, állcsont-, szájsebészet, egészség-gazdasá...</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Arc- Állcsont- Szájsebészeti és Fogászati Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013989"><a href="/gui2/?type=authors&mode=browse&sel=10013989" target="_blank">Putz Zsuzsanna (<span class="authorship-author-name">Putz Zsuzsanna</span> <span class="authorAux-mtmt"> Belgyógyászat, diabetológia, klinikofarmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Belgyógyászati és Onkológiai Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Belgyógyászati és Onkológiai Klinika">BOK</span>/HUN-REN-SE Endokrin Molekuláris Patológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024099"><a href="/gui2/?type=authors&mode=browse&sel=10024099" target="_blank">Kosa Janos P.^** (<span class="authorship-author-name">Kósa János</span> <span class="authorAux-mtmt"> molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Belgyógyászati és Onkológiai Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Belgyógyászati és Onkológiai Klinika">BOK</span>/HUN-REN-SE Endokrin Molekuláris Patológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10012016"><a href="/gui2/?type=authors&mode=browse&sel=10012016" target="_blank">Lakatos Peter ✉ (<span class="authorship-author-name">Lakatos Péter</span> <span class="authorAux-mtmt"> Osteológia, endokrinológia, molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Belgyógyászati és Onkológiai Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Belgyógyászati és Onkológiai Klinika">BOK</span>/HUN-REN-SE Endokrin Molekuláris Patológiai Kutatócsoport</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35430277" target="_blank">Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives</a></div> <div> <span class="journal-title">INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1661-6596">1661-6596</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1422-0067">1422-0067</a>)</span>: <span class="journal-volume">25</span> <span class="journal-issue">19</span> <span class="page"> Paper 10488. 17 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3390/ijms251910488" target="_blank" href="https://doi.org/10.3390/ijms251910488"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001332401600001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001332401600001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85206341318" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85206341318"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39408816" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39408816&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Organic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Spectroscopy&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Computer Science Applications&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Inorganic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Physical and Theoretical Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Catalysis&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Biology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 9</span> | Független: 8 | Függő: 1 | Nem jelölt: 0 | WoS jelölt: 6 | Scopus jelölt:&nbsp;6 | WoS/Scopus jelölt:&nbsp;6 | DOI jelölt:&nbsp;8 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35430277&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 5 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35430277</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (2020- 4.1.1.-TKP2020-MOLORKIV), (SE-ELKH ENDOMOLPAT) </div> <div class="lastModified">Utolsó módosítás: 2025.04.25. 09:26 Csernyik Rita (MTMT központi admin) </div> <div class="lockedBy">Központi kezelésű 2025.04.25. 08:19 Csernyik Rita (MTMT központi admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Megosztott utolsó szerzőség</pre> </div></div>